Cargando…

Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?

The absence of a specific treatment for SARS-CoV-2 infection led to an intense global effort in order to find new therapeutic interventions and improve patient outcomes. One important feature of COVID-19 pathophysiology is the activation of immune cells, with consequent massive production and releas...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Luis H.A., Santos, Bruna M., Branco, Luiz G.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832208/
https://www.ncbi.nlm.nih.gov/pubmed/33022271
http://dx.doi.org/10.1016/j.ejphar.2020.173629
_version_ 1783641785576194048
author Costa, Luis H.A.
Santos, Bruna M.
Branco, Luiz G.S.
author_facet Costa, Luis H.A.
Santos, Bruna M.
Branco, Luiz G.S.
author_sort Costa, Luis H.A.
collection PubMed
description The absence of a specific treatment for SARS-CoV-2 infection led to an intense global effort in order to find new therapeutic interventions and improve patient outcomes. One important feature of COVID-19 pathophysiology is the activation of immune cells, with consequent massive production and release of inflammatory mediators that may cause impairment of several organ functions, including the brain. In addition to its classical role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5-HT) has immunomodulatory properties, downregulating the inflammatory response by central and peripheral mechanisms. In this review, we describe the roles of 5-HT in the regulation of systemic inflammation and the potential benefits of the use of specific serotonin reuptake inhibitors as a coadjutant therapy to attenuate neurological complications of COVID-19.
format Online
Article
Text
id pubmed-7832208
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78322082021-01-26 Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19? Costa, Luis H.A. Santos, Bruna M. Branco, Luiz G.S. Eur J Pharmacol Full Length Article The absence of a specific treatment for SARS-CoV-2 infection led to an intense global effort in order to find new therapeutic interventions and improve patient outcomes. One important feature of COVID-19 pathophysiology is the activation of immune cells, with consequent massive production and release of inflammatory mediators that may cause impairment of several organ functions, including the brain. In addition to its classical role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5-HT) has immunomodulatory properties, downregulating the inflammatory response by central and peripheral mechanisms. In this review, we describe the roles of 5-HT in the regulation of systemic inflammation and the potential benefits of the use of specific serotonin reuptake inhibitors as a coadjutant therapy to attenuate neurological complications of COVID-19. Elsevier B.V. 2020-12-15 2020-10-03 /pmc/articles/PMC7832208/ /pubmed/33022271 http://dx.doi.org/10.1016/j.ejphar.2020.173629 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Length Article
Costa, Luis H.A.
Santos, Bruna M.
Branco, Luiz G.S.
Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
title Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
title_full Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
title_fullStr Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
title_full_unstemmed Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
title_short Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
title_sort can selective serotonin reuptake inhibitors have a neuroprotective effect during covid-19?
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832208/
https://www.ncbi.nlm.nih.gov/pubmed/33022271
http://dx.doi.org/10.1016/j.ejphar.2020.173629
work_keys_str_mv AT costaluisha canselectiveserotoninreuptakeinhibitorshaveaneuroprotectiveeffectduringcovid19
AT santosbrunam canselectiveserotoninreuptakeinhibitorshaveaneuroprotectiveeffectduringcovid19
AT brancoluizgs canselectiveserotoninreuptakeinhibitorshaveaneuroprotectiveeffectduringcovid19